18F-FDG PET CT as a prognostic factor in hepatocellular carcinoma

Cho, Eunae; Jun, Chung Hwan; Kim, Ban Seok; Son, Dong Jun; Choi, Won Suk; Choi, Sung Kyu

doi:10.5152/tjg.2015.0152

Cited by 16 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The stage incorporation and analysis was weakly associated with outcome, so the multivariate analysis included significant components of this staging system that had stronger associations with outcome on UVA ( i.e ., ECOG Performance status, extrahepatic disease, and tumor burden) (Table 3). Despite these limitations, our results were in line with other studies that found a similar prognostic benefit to pre-treatment FDG-PET/CT scans in patients getting treated for HCC[16-22]. …”

Section: Discussionsupporting

confidence: 91%

“…The role of FDG-PET in the assessment of different treatment modalities for HCC has been described in several reports[16-22]. Pant et al[17] assessed pre-treatment FDG-avidity as a prognostic index in the management of HCC in 100 patients.…”

Section: Discussionmentioning

confidence: 99%

“…The role of FDG-PET scans for patients with hepatocellular carcinoma has also been assessed in patients following trans-arterial chemotherapy embolization (TACE)[16,18]. Cho et al[16] found after a mean follow-up of 8 months (range, 1-59 mo), among the 47 patients who underwent TACE, a higher ratio of tumor SUV max to mean mediastinal SUV of ≥ 3.1 was associated with higher rates of recurrence and lower survival (94% vs 64%, P = 0.016).…”

Section: Discussionmentioning

confidence: 99%

“…Cho et al[16] found after a mean follow-up of 8 months (range, 1-59 mo), among the 47 patients who underwent TACE, a higher ratio of tumor SUV max to mean mediastinal SUV of ≥ 3.1 was associated with higher rates of recurrence and lower survival (94% vs 64%, P = 0.016). Kim et al[18] showed that SUV max to mean liver SUV ratio of 1.83 was a predictor for disease progression and worse OS.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization

Abuodeh

Naghavi

Ahmed

et al. 2016

WJG

View full text Add to dashboard Cite

AIMTo evaluate the value of pre-treatment 18F-FDG PET/CT in patients with HCC following liver radioembolization.METHODSWe identified 34 patients with HCC who underwent an FDG PET/CT scan prior to hepatic radioembolization at our institution between 2009 and 2013. Patients were seen in clinic one month after radioembolization and then at 2-3 mo intervals. We assessed the influence of FDG tumor uptake on outcomes including local liver control (LLC), distant liver control (DLC), time to distant metastases (DM), progression free survival (PFS) and overall survival (OS).RESULTSThe majority of patients were males (n = 25, 74%), and had Child Pugh Class A (n = 31, 91%), with a median age of 68 years (46-84 years). FDG-avid disease was found in 19 (56%) patients with SUVmax ranging from 3 to 20. Female patients were more likely to have an FDG-avid HCC (P = 0.02). Median follow up of patients following radioembolization was 12 months (1.2-62.8 mo). FDG-avid disease was associated with a decreased 1 year LLC, DLC, DM and PFS (P < 0.05). Using multivariate analysis, FDG avidity predicted for LLC, DLC, and PFS (all P < 0.05).CONCLUSIONIn this retrospective study, pre-treatment HCC FDG-avidity was found to be associated with worse LLC, DLC, and PFS following radioembolization. Larger studies are needed to validate our initial findings to assess the role of F-18-FDG PET/CT scans as biomarker for patients with HCC following radioembolization.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization

Abuodeh

Naghavi

Ahmed

et al. 2016

WJG

View full text Add to dashboard Cite

show abstract

“…Pode-se monitorar de forma não invasiva a instalação e progressão do CHC, quantificando a carga tumoral, identificando sítios metastáticos e quantificando a resposta ao tratamento por uma droga em teste (74) . (74,(83)(84)(85)(86)(87)(88) . Isto também foi visto na linhagem celular de CHC, pois a ausência da expressão da p53 levou a maior captação do 18 F-FDG, sendo portanto indicativo de pior prognóstico (80) .…”

Section: Pet E Chcunclassified